You are here

  • Home
  • Archive
  • Volume 72, Issue 8
  • Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance

Article metrics

Article menu
Hepatology
Original research
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance

 

Online download statistics by month:

Online download statistics by month: October 2022 to March 2024

AbstractFullPdf
Oct 2022969917
Nov 202214771452625
Dec 2022560548117
Jan 202326825976
Feb 2023268259100
Mar 202324122877
Apr 202315314852
May 202316615862
Jun 202318617676
Jul 2023648638307
Aug 202312341205123
Sep 20231394138092
Oct 20231804178372
Nov 20231515149578
Dec 202312031169108
Jan 20241432141386
Feb 20241137111664
Mar 202413651355150
Total15147148812282